Complete Response to the Combination of Pembrolizumab and Sorafenib for Metastatic Hepatocellular Carcinoma: A Case Report

1Division of Hematology, Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan 2Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, Taipei, Taiwan 3Faculty of Medicine, National Yang Ming University, Taipei, Taiwan 4Institute of Clinical Medicine, National Yang Ming University, Taipei, Taiwan 5Genome Research Center, National Yang Ming University, Taipei, Taiwan Correspondence: Muh-Hwa Yang, MD, PhD, Division of Medical Oncology, Department of Oncology, Taipei Veterans General Hospital, No. 201, Sec. 2, Shipai Road, Taipei 11217, Taiwan E-mail: [email protected] The authors declare no conflict of interest.